EBEwa Błaszczak

Ewa Błaszczak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ewa Błaszczak has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characterization of the cellular network of ubiquitin conjugating and ligating enzymes

    by Ewa Katarzyna Blaszczak

    Caractérisation du réseau cellulaire d'enzymes de conjugaison et de ligation de l'ubiquitine: L'ubiquitylation des protéines est une modification post-traductionnelle qui joue un rôle capital dans la régulation des nombreuses fonctions cellulaires, y compris la croissance cellulaire et la prolifération. Les dysfonctionnements de ce mécanisme sont à l'origine de diverses maladies telles que le cancer par exemple. Le processus d'ubiquitylation implique une série des réactions enzymatiques en cascade, catalysées par une famille des enzymes, structuralement très proches. Cette famille est composée des enzymes activateurs d'ubiquitine (E1s), des enzymes de conjugaison d'ubiquitine (E2s) et des ligases d'ubiquitine (E3s). Les interactions entre E2s et E3s sont dans le centre de la cascade d'ubiquitylation. Une combinaison particulière des pairs E2/E3 va déterminer le type de chaînes d'ubiquitine qui seront attachées à la protéine d'intérêt pour ensuite déterminer la fonction régulatrice de la voie d'ubiquitylation. A ce jour, seulement une petite fraction de paires possibles entre E2 et E3 a été investiguée par des approches biochimiques et in vitro. Cependant ces approches ne reflètent pas forcément des conditions qu'on trouve dans une cellule vivante. Prenant ceci en considération, les principales objectives de ma thèse seront comme suit : identifier et optimiser une méthode de détection et de quantification des interactions E2/E3 dans une cellule vivante de la levure de boulanger (Saccharomyces cerevisiae) ; construire une bibliothèque de souches de la levure qui permettrait d'établir des interactions entre E2 et E3 ; chercher de nouvelles potentielles paires E2/E3 ; caractériser fonctionnellement une potentielle paire E2/E2. Il est difficile de trouver une méthodologie appropriée afin d'étudier les interactions entre E2 et E3 parce qu'ils sont relativement faibles et transitoires. Leurs études nécessitent donc des techniques de détection avec une grande sensibilité. Parmi différentes techniques nous avons testé et choisi la complémentation bimoléculaire de la fluorescence, BiFC. Kurtosis, une mesure permettant localiser et quantifier la fluorescence BiFC-spécifique. Nos résultats nous nous avons permis à identifier 117 putatives paires E2/E3 parmi quels, 23 paires ont été déjà décrit dans la littérature. Parmi 94 nouvelles paires, certains E3s interagissent avec seulement une seule E2 ou d'autres donnent un signal BiFC avec plusieurs E2s. Ubc13, Ubc1 et Ubc4 sont les E2s qui interagissent le plus souvent. Nous avons identifié aussi une interaction entre les protéines Asi1 et Asi3 et les enzymes de conjugaison d'ubiquitine Ubc6 et Ubc7. Asi1 et 3 sont connus de former un complexe Asi1/3 sur la membrane intérieure du noyau impliqué dans la réponse de la cellule aux acides aminés extracellulaires. Ces protéines contiennent un domaine RING caractéristique pour les ligases d'ubiquitine mais cette activité n'était pas démontrée auparavant.

  • Open Access

    Bilosomal Encapsulation of Binuclear Phosphino Ru(II)–Cu(II) Compounds Enhances Their Selectivity and Activity toward Lung and Prostate Cancers

    by Sandra Kozieł, Daria Wojtala, Agata Barzowska-Gogola, Barbara Pucelik, Ewelina Waglewska, Miłosz Siczek, Maciej Witwicki, Alessandro Niorettini, Agnieszka Kyzioł, Magdalena Malik, et al.

    This study reports the synthesis, characterization, and biological evaluation of four novel heteronuclear Ru(II)-Cu(II) complexes with phosphine-fluoroquinolone conjugates. Structural analysis using X-ray diffraction, density functional theory calculations, and various spectroscopic techniques confirmed the stability and coordination geometries. The cytotoxicity was evaluated in vitro across multiple cancer cell lines (lung, breast, pancreatic, prostate) and noncancerous cells. In vivo toxicity was also assessed using a zebrafish (Danio rerio) larvae model. The results demonstrated that Ru(II)-Cu(II) complexes exhibit greater anticancer activity compared with cisplatin while almost being nontoxic toward control cells in vitro. Mechanistic studies revealed that their action involves nuclei accumulation, reactive oxygen species generation, lipid peroxidation, and mitochondrial membrane depolarization. The expression ratio of Bax to Bcl-2 mRNA correlates with apoptotic cell death. Additionally, encapsulation of the one Ru(II)-Cu(II) complex in bilosomes significantly improved its stability, selectivity, and therapeutic efficacy in three-dimensional (3D) cancer spheroid models.


  • Open Access

    Advancing Head and Neck Cancer Therapies: From Conventional Treatments to Emerging Strategies

    by Aleksandra Mordzińska-Rak, Ilona Telejko, Grzegorz Adamczuk, Tomasz Trombik, Andrzej Stepulak, Ewa Błaszczak

    Head and neck cancers (HNCs), particularly head and neck squamous cell carcinoma (HNSCC), are among the most aggressive and prevalent malignancies of the upper aerodigestive tract. As the incidence of HNCs continues to rise, this cancer type presents a significant public health challenge. Despite conventional treatment options, such as surgery, chemotherapy, and radiotherapy, the five-year survival rates remain relatively low due to resistance to these therapies, local recurrence, local lymph node metastasis, and in some advanced cases also distant metastasis. Consequently, patients with HNCs face a high mortality risk and have reduced quality of life due to the side effects of chemo- and radiotherapy. Furthermore, targeted therapies and immunotherapies have also shown limited effectiveness in many cases, with issues related to resistance and the accessibility of these treatments. Therefore, new strategies, such as those based on combination therapies and nanotechnology, are being explored to improve the treatment of HNC patients. The proteolysis-targeting chimeras (PROTACs) also emerged as a promising therapeutic approach, though research is still ongoing to bring this technology into clinical practice. Here, we aim to highlight the current knowledge of HNC therapies, with a focus on recent advancements, including nanomedicine and PROTAC-based strategies. The development and advancement of novel emerging therapies hold promise for the improvement of patients’ survival and quality of life.


  • Open Access

    Dysregulation of cholesterol homeostasis in cancer pathogenesis

    by Aleksandra Mordzińska-Rak, Grégory Verdeil, Yannick Hamon, Ewa Błaszczak, Tomasz Trombik

    Cholesterol is a unique lipid for all mammalian cells, with important functions in membrane biogenesis and maintenance of proper membrane integrity and fluidity. Therefore, it plays an important role in cellular homeostasis. Dysregulation of cholesterol homeostasis is associated with various diseases in humans, including cardiovascular diseases, inflammatory diseases, neurodegenerative disorders, and cancers. In the tumor microenvironment, intrinsic and extrinsic cellular factors reprogram cholesterol metabolism and consequently promote tumorigenesis. Here, we summarize the current knowledge on molecular mechanisms and functional roles of cholesterol homeostasis and its dysregulation in regard to cancer pathogenesis. We also discuss the interplay of cholesterol metabolism and the ATP-binding cassette (ABC) proteins, highly conserved cellular transmembrane lipid transporters. An emerging role of lipid ABC transporters as potential prognostic tools for cancer progression and invasiveness is emphasized. Targeting both cholesterol metabolism and proteins associated with membrane cholesterol holds promise as a novel therapeutic strategy for cancer treatment.


  • Top Cited Papers
    Open Access

    Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition

    by Ewa Błaszczak, Paulina Miziak, Adrian Odrzywolski, Marzena Baran, Ewelina Gumbarewicz, Andrzej Stepulak

    Triple-negative breast cancer (TNBC) is one of the most difficult subtypes of breast cancer to treat due to its distinct clinical and molecular characteristics. Patients with TNBC face a high recurrence rate, an increased risk of metastasis, and lower overall survival compared to other breast cancer subtypes. Despite advancements in targeted therapies, traditional chemotherapy (primarily using platinum compounds and taxanes) continues to be the standard treatment for TNBC, often with limited long-term efficacy. TNBC tumors are heterogeneous, displaying a diverse mutation profile and considerable chromosomal instability, which complicates therapeutic interventions. The development of chemoresistance in TNBC is frequently associated with the process of epithelial–mesenchymal transition (EMT), during which epithelial tumor cells acquire a mesenchymal-like phenotype. This shift enhances metastatic potential, while simultaneously reducing the effectiveness of standard chemotherapeutics. It has also been suggested that EMT plays a central role in the development of cancer stem cells. Hence, there is growing interest in exploring small-molecule inhibitors that target the EMT process as a future strategy for overcoming resistance and improving outcomes for patients with TNBC. This review focuses on the progression and drug resistance of TNBC with an emphasis on the role of EMT in these processes. We present TNBC-specific and EMT-related molecular features, key EMT protein markers, and various signaling pathways involved. We also discuss other important mechanisms and factors related to chemoresistance in TNBC within the context of EMT, highlighting treatment advancements to improve patients’ outcomes.


  • Open Access

    Current state of melanoma treatment – from conventional therapies to nanotechnology and beyond

    by Danuta Krasowska, Jacek Kurzepa, Ewa Błaszczak

    Introduction and objective: Melanoma is recognized as the most aggressive type of skin cancer, and its global incidence is rising. Early detection of melanoma is crucial, as it allows for curative surgical removal with clear margins based on the tumour’s depth. However, managing advanced...


  • Open Access

    Transcription Factors and Markers Related to Epithelial–Mesenchymal Transition and Their Role in Resistance to Therapies in Head and Neck Cancers

    by Marta Pawlicka, Ewelina Gumbarewicz, Ewa Błaszczak, Andrzej Stepulak

    Head and neck cancers (HNCs) are heterogeneous and aggressive tumors of the upper aerodigestive tract. Although various histological types exist, the most common is squamous cell carcinoma (HNSCC). The incidence of HNSCC is increasing, making it an important public health concern. Tumor resistance to contemporary treatments, namely, chemo- and radiotherapy, and the recurrence of the primary tumor after its surgical removal cause huge problems for patients. Despite recent improvements in these treatments, the 5-year survival rate is still relatively low. HNSCCs may develop local lymph node metastases and, in the most advanced cases, also distant metastases. A key process associated with tumor progression and metastasis is epithelial–mesenchymal transition (EMT), when poorly motile epithelial tumor cells acquire motile mesenchymal characteristics. These transition cells can invade different adjacent tissues and finally form metastases. EMT is governed by various transcription factors, including the best-characterized TWIST1 and TWIST2, SNAIL, SLUG, ZEB1, and ZEB2. Here, we highlight the current knowledge of the process of EMT in HNSCC and present the main protein markers associated with it. This review focuses on the transcription factors related to EMT and emphasizes their role in the resistance of HNSCC to current chemo- and radiotherapies. Understanding the role of EMT and the precise molecular mechanisms involved in this process may help with the development of novel anti-cancer therapies for this type of tumor.


  • Open Access

    Dissecting Ubiquitylation and DNA Damage Response Pathways in the Yeast Saccharomyces cerevisiae Using a Proteome-Wide Approach

    by Ewa Blaszczak, Emeline Pasquier, Gaëlle Le Dez, Adrian Odrzywolski, Natalia Lazarewicz, Audrey Brossard, Emilia Fornal, Piotr Moskalek, Robert Wysocki, Gwenaël Rabut


  • Top Cited Papers
    Open Access

    Estrogen Receptor Signaling in Breast Cancer

    by Paulina Miziak, Marzena Baran, Ewa Błaszczak, Alicja Przybyszewska-Podstawka, Joanna Kałafut, Jolanta Smok-Kalwat, Magdalena Dmoszyńska-Graniczka, Michał Kiełbus, Andrzej Stepulak

    Estrogen receptor (ER) signaling is a critical regulator of cell proliferation, differentiation, and survival in breast cancer (BC) and other hormone-sensitive cancers. In this review, we explore the mechanism of ER-dependent downstream signaling in BC and the role of estrogens as growth factors necessary for cancer invasion and dissemination. The significance of the clinical implications of ER signaling in BC, including the potential of endocrine therapies that target estrogens’ synthesis and ER-dependent signal transmission, such as aromatase inhibitors or selective estrogen receptor modulators, is discussed. As a consequence, the challenges associated with the resistance to these therapies resulting from acquired ER mutations and potential strategies to overcome them are the critical point for the new treatment strategies’ development.


  • Open Access

    Protein-fragment complementation assays for large-scale analysis of protein–protein interactions

    by Ewa Blaszczak, Natalia Lazarewicz, Aswani Sudevan, Robert Wysocki, Gwenaël Rabut

    Protein–protein interactions (PPIs) orchestrate nearly all biological processes. They are also considered attractive drug targets for treating many human diseases, including cancers and neurodegenerative disorders. Protein-fragment complementation assays (PCAs) provide a direct and straightforward way to study PPIs in living cells or multicellular organisms. Importantly, PCAs can be used to detect the interaction of proteins expressed at endogenous levels in their native cellular environment. In this review, we present the principle of PCAs and discuss some of their advantages and limitations. We describe their application in large-scale experiments to investigate PPI networks and to screen or profile PPI targeting compounds.